### Comment:
You’re correct in that the KDA risk is there, but compare this drug to primlamtide, I see a similar situation between the two and really, I see a black box label as a reasonable outcome. Of course, along with a request for further trialing.

### REPLY:
Black box label for sure, that's what we've got on the SGLT2 inhibs. I see it as getting approved but not used much. They didn't research all cause mortality which they should have, so that will limit how much they use it. I wanted to read their entire clinical trials history on the drug but they didnt publish any results, which annoys me and is a negative sign for me. Regardless I snagged a few shares to see the pop for approval. If it doesn't then I'll just bag hold for a while.

### END.